Sentinel lymph node biopsy in melanoma: beyond histologic factors
Sentinel lymph node (SLN) biopsy should be performed with the technical expertise required to correctly identify the sentinel node, in the context of understanding both the likelihood of positivity in a given patient and the prognostic significance of a positive or negative result. National Comprehe...
Gespeichert in:
| Veröffentlicht in: | Clinical & experimental metastasis 2022-02, Vol.39 (1), p.29-38 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 38 |
|---|---|
| container_issue | 1 |
| container_start_page | 29 |
| container_title | Clinical & experimental metastasis |
| container_volume | 39 |
| creator | Carr, Michael J. Monzon, Federico A. Zager, Jonathan S. |
| description | Sentinel lymph node (SLN) biopsy should be performed with the technical expertise required to correctly identify the sentinel node, in the context of understanding both the likelihood of positivity in a given patient and the prognostic significance of a positive or negative result. National Comprehensive Cancer Network guidelines recommend SLN biopsy for all cutaneous melanoma patients with primary tumor thickness greater than 1 mm and in select patients with thickness between 0.8 and 1 mm, yet admit a lack of consistent clarity in its utility for prognosis and therapeutic value in tumors |
| doi_str_mv | 10.1007/s10585-021-10089-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2539205306</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2645318286</sourcerecordid><originalsourceid>FETCH-LOGICAL-c375t-33ec144dab2779277e43611f912a6b7f986f53e2ec32c76252a90cc4dcf12fc23</originalsourceid><addsrcrecordid>eNp9kM1KxDAURoMozjj6Ai6k4MZNNblpksadDP7BgAt1Hdo0menQNrVpF317M3ZUcOEihHDP9-VyEDon-JpgLG48wSxlMQYSh3cqY3mA5oQJGgsQ_BDNMXCIwyCdoRPvtxjjRIj0GM1oEgJE8jm6ezVNXzamiqqxbjdR4woT5aVr_RiVTVSbKmtcnd1GuRldU0Sb0veucutSRzbTvev8KTqyWeXN2f5eoPeH-7flU7x6eXxe3q1iTQXrY0qNJklSZDkIIcMxCeWEWEkg47mwMuWWUQNGU9CCA4NMYq2TQlsCVgNdoKupt-3cx2B8r-rSa1OFBY0bvAJGJWBGMQ_o5R9064auCdsp4AmjJIV0R8FE6c553xmr2q6ss25UBKudYDUJVkGw-hKsZAhd7KuHvDbFT-TbaADoBPgwatam-_37n9pPmGCEog</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2645318286</pqid></control><display><type>article</type><title>Sentinel lymph node biopsy in melanoma: beyond histologic factors</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Carr, Michael J. ; Monzon, Federico A. ; Zager, Jonathan S.</creator><creatorcontrib>Carr, Michael J. ; Monzon, Federico A. ; Zager, Jonathan S.</creatorcontrib><description>Sentinel lymph node (SLN) biopsy should be performed with the technical expertise required to correctly identify the sentinel node, in the context of understanding both the likelihood of positivity in a given patient and the prognostic significance of a positive or negative result. National Comprehensive Cancer Network guidelines recommend SLN biopsy for all cutaneous melanoma patients with primary tumor thickness greater than 1 mm and in select patients with thickness between 0.8 and 1 mm, yet admit a lack of consistent clarity in its utility for prognosis and therapeutic value in tumors < 1 mm and leave the decision for undergoing the procedure up to the patient and treating physician. Recent studies have evaluated specific patient populations, tumor histopathologic characteristics, and gene expression profiling and their use in predicting SLN positivity. These data have given insight into improving the physician’s ability to potentially predict SLN positivity, shedding light on if and when omission of SLN biopsy in specific patients based on clinicopathological characteristics might be appropriate. This review provides discussion and insight into these recent advancements.</description><identifier>ISSN: 0262-0898</identifier><identifier>EISSN: 1573-7276</identifier><identifier>DOI: 10.1007/s10585-021-10089-9</identifier><identifier>PMID: 34100196</identifier><language>eng</language><publisher>Dordrecht: Springer Netherlands</publisher><subject>Biomedical and Life Sciences ; Biomedicine ; Biopsy ; Cancer Research ; Gene expression ; Hematology ; Humans ; Lymph nodes ; Lymph Nodes - pathology ; Lymphatic Metastasis - pathology ; Lymphatic system ; Melanoma ; Melanoma - pathology ; Melanoma - surgery ; Oncology ; Patients ; Prognosis ; Review ; Sentinel Lymph Node - pathology ; Sentinel Lymph Node - surgery ; Sentinel Lymph Node Biopsy - methods ; Skin Neoplasms - pathology ; Skin Neoplasms - surgery ; Surgical Oncology ; Thickness ; Tumors</subject><ispartof>Clinical & experimental metastasis, 2022-02, Vol.39 (1), p.29-38</ispartof><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2021</rights><rights>2021. The Author(s), under exclusive licence to Springer Nature B.V.</rights><rights>The Author(s), under exclusive licence to Springer Nature B.V. 2021.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c375t-33ec144dab2779277e43611f912a6b7f986f53e2ec32c76252a90cc4dcf12fc23</citedby><cites>FETCH-LOGICAL-c375t-33ec144dab2779277e43611f912a6b7f986f53e2ec32c76252a90cc4dcf12fc23</cites><orcidid>0000-0001-6233-4004 ; 0000-0002-6886-4468</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s10585-021-10089-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s10585-021-10089-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34100196$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carr, Michael J.</creatorcontrib><creatorcontrib>Monzon, Federico A.</creatorcontrib><creatorcontrib>Zager, Jonathan S.</creatorcontrib><title>Sentinel lymph node biopsy in melanoma: beyond histologic factors</title><title>Clinical & experimental metastasis</title><addtitle>Clin Exp Metastasis</addtitle><addtitle>Clin Exp Metastasis</addtitle><description>Sentinel lymph node (SLN) biopsy should be performed with the technical expertise required to correctly identify the sentinel node, in the context of understanding both the likelihood of positivity in a given patient and the prognostic significance of a positive or negative result. National Comprehensive Cancer Network guidelines recommend SLN biopsy for all cutaneous melanoma patients with primary tumor thickness greater than 1 mm and in select patients with thickness between 0.8 and 1 mm, yet admit a lack of consistent clarity in its utility for prognosis and therapeutic value in tumors < 1 mm and leave the decision for undergoing the procedure up to the patient and treating physician. Recent studies have evaluated specific patient populations, tumor histopathologic characteristics, and gene expression profiling and their use in predicting SLN positivity. These data have given insight into improving the physician’s ability to potentially predict SLN positivity, shedding light on if and when omission of SLN biopsy in specific patients based on clinicopathological characteristics might be appropriate. This review provides discussion and insight into these recent advancements.</description><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Biopsy</subject><subject>Cancer Research</subject><subject>Gene expression</subject><subject>Hematology</subject><subject>Humans</subject><subject>Lymph nodes</subject><subject>Lymph Nodes - pathology</subject><subject>Lymphatic Metastasis - pathology</subject><subject>Lymphatic system</subject><subject>Melanoma</subject><subject>Melanoma - pathology</subject><subject>Melanoma - surgery</subject><subject>Oncology</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Review</subject><subject>Sentinel Lymph Node - pathology</subject><subject>Sentinel Lymph Node - surgery</subject><subject>Sentinel Lymph Node Biopsy - methods</subject><subject>Skin Neoplasms - pathology</subject><subject>Skin Neoplasms - surgery</subject><subject>Surgical Oncology</subject><subject>Thickness</subject><subject>Tumors</subject><issn>0262-0898</issn><issn>1573-7276</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kM1KxDAURoMozjj6Ai6k4MZNNblpksadDP7BgAt1Hdo0menQNrVpF317M3ZUcOEihHDP9-VyEDon-JpgLG48wSxlMQYSh3cqY3mA5oQJGgsQ_BDNMXCIwyCdoRPvtxjjRIj0GM1oEgJE8jm6ezVNXzamiqqxbjdR4woT5aVr_RiVTVSbKmtcnd1GuRldU0Sb0veucutSRzbTvev8KTqyWeXN2f5eoPeH-7flU7x6eXxe3q1iTQXrY0qNJklSZDkIIcMxCeWEWEkg47mwMuWWUQNGU9CCA4NMYq2TQlsCVgNdoKupt-3cx2B8r-rSa1OFBY0bvAJGJWBGMQ_o5R9064auCdsp4AmjJIV0R8FE6c553xmr2q6ss25UBKudYDUJVkGw-hKsZAhd7KuHvDbFT-TbaADoBPgwatam-_37n9pPmGCEog</recordid><startdate>20220201</startdate><enddate>20220201</enddate><creator>Carr, Michael J.</creator><creator>Monzon, Federico A.</creator><creator>Zager, Jonathan S.</creator><general>Springer Netherlands</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8FE</scope><scope>8FG</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ARAPS</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>BGLVJ</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>P5Z</scope><scope>P62</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-6233-4004</orcidid><orcidid>https://orcid.org/0000-0002-6886-4468</orcidid></search><sort><creationdate>20220201</creationdate><title>Sentinel lymph node biopsy in melanoma: beyond histologic factors</title><author>Carr, Michael J. ; Monzon, Federico A. ; Zager, Jonathan S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c375t-33ec144dab2779277e43611f912a6b7f986f53e2ec32c76252a90cc4dcf12fc23</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Biopsy</topic><topic>Cancer Research</topic><topic>Gene expression</topic><topic>Hematology</topic><topic>Humans</topic><topic>Lymph nodes</topic><topic>Lymph Nodes - pathology</topic><topic>Lymphatic Metastasis - pathology</topic><topic>Lymphatic system</topic><topic>Melanoma</topic><topic>Melanoma - pathology</topic><topic>Melanoma - surgery</topic><topic>Oncology</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Review</topic><topic>Sentinel Lymph Node - pathology</topic><topic>Sentinel Lymph Node - surgery</topic><topic>Sentinel Lymph Node Biopsy - methods</topic><topic>Skin Neoplasms - pathology</topic><topic>Skin Neoplasms - surgery</topic><topic>Surgical Oncology</topic><topic>Thickness</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carr, Michael J.</creatorcontrib><creatorcontrib>Monzon, Federico A.</creatorcontrib><creatorcontrib>Zager, Jonathan S.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Technology Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Advanced Technologies & Aerospace Collection</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Technology Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Advanced Technologies & Aerospace Database</collection><collection>ProQuest Advanced Technologies & Aerospace Collection</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical & experimental metastasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carr, Michael J.</au><au>Monzon, Federico A.</au><au>Zager, Jonathan S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Sentinel lymph node biopsy in melanoma: beyond histologic factors</atitle><jtitle>Clinical & experimental metastasis</jtitle><stitle>Clin Exp Metastasis</stitle><addtitle>Clin Exp Metastasis</addtitle><date>2022-02-01</date><risdate>2022</risdate><volume>39</volume><issue>1</issue><spage>29</spage><epage>38</epage><pages>29-38</pages><issn>0262-0898</issn><eissn>1573-7276</eissn><abstract>Sentinel lymph node (SLN) biopsy should be performed with the technical expertise required to correctly identify the sentinel node, in the context of understanding both the likelihood of positivity in a given patient and the prognostic significance of a positive or negative result. National Comprehensive Cancer Network guidelines recommend SLN biopsy for all cutaneous melanoma patients with primary tumor thickness greater than 1 mm and in select patients with thickness between 0.8 and 1 mm, yet admit a lack of consistent clarity in its utility for prognosis and therapeutic value in tumors < 1 mm and leave the decision for undergoing the procedure up to the patient and treating physician. Recent studies have evaluated specific patient populations, tumor histopathologic characteristics, and gene expression profiling and their use in predicting SLN positivity. These data have given insight into improving the physician’s ability to potentially predict SLN positivity, shedding light on if and when omission of SLN biopsy in specific patients based on clinicopathological characteristics might be appropriate. This review provides discussion and insight into these recent advancements.</abstract><cop>Dordrecht</cop><pub>Springer Netherlands</pub><pmid>34100196</pmid><doi>10.1007/s10585-021-10089-9</doi><tpages>10</tpages><orcidid>https://orcid.org/0000-0001-6233-4004</orcidid><orcidid>https://orcid.org/0000-0002-6886-4468</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0262-0898 |
| ispartof | Clinical & experimental metastasis, 2022-02, Vol.39 (1), p.29-38 |
| issn | 0262-0898 1573-7276 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2539205306 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Biomedical and Life Sciences Biomedicine Biopsy Cancer Research Gene expression Hematology Humans Lymph nodes Lymph Nodes - pathology Lymphatic Metastasis - pathology Lymphatic system Melanoma Melanoma - pathology Melanoma - surgery Oncology Patients Prognosis Review Sentinel Lymph Node - pathology Sentinel Lymph Node - surgery Sentinel Lymph Node Biopsy - methods Skin Neoplasms - pathology Skin Neoplasms - surgery Surgical Oncology Thickness Tumors |
| title | Sentinel lymph node biopsy in melanoma: beyond histologic factors |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T18%3A49%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Sentinel%20lymph%20node%20biopsy%20in%20melanoma:%20beyond%20histologic%20factors&rft.jtitle=Clinical%20&%20experimental%20metastasis&rft.au=Carr,%20Michael%20J.&rft.date=2022-02-01&rft.volume=39&rft.issue=1&rft.spage=29&rft.epage=38&rft.pages=29-38&rft.issn=0262-0898&rft.eissn=1573-7276&rft_id=info:doi/10.1007/s10585-021-10089-9&rft_dat=%3Cproquest_cross%3E2645318286%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2645318286&rft_id=info:pmid/34100196&rfr_iscdi=true |